Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
NCT ID: NCT02931136
Last Updated: 2019-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
300 participants
INTERVENTIONAL
2019-11-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination
NCT04305210
A Multicenter Study on the Diagnosis and Intervention of New Biomarkers on the Prodromal Stage of Alzheimer's Disease
NCT04137926
Analysis of XTR006 PET Imaging in Non-cognitively Impaired Subjects, MCI Due toAD, and Mild to Moderate AD Subjects
NCT06151808
Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
NCT01265394
Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
NCT01202994
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
treatment group
Huperzine A treatment.
Huperzine A
The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
Placebo group
The placebo in 52 weeks.
Placebo
The participants will treatment by the placebo in 52 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Huperzine A
The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
Placebo
The participants will treatment by the placebo in 52 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* objective memory impairment.
* normal general cognitive function.
* intact activities of daily living.
* absence of dementia.
* the positive of brain senile plaque.
Exclusion Criteria
* other type of dementia except AD
55 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Mental Health Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
xiaoshifu
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shifu Xiao, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Shanghai Mental Health Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Shanghai Mental Health Center
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.